Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53

Oncogene

Volumn 26, Issue 46, 2007, Pages 6653-6664

  Chipoy, C ^a,b,c   Brounais, B ^a,b   Trichet, V ^a,b   Battaglia, S ^a,b   Berreur, M ^a,b   Oliver, L ^a   Juin, P ^a   Redini F ^a,b   Heymann, D ^a,b   Blanchard, F ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Universite de Nantes   (France)

Author keywords

Apoptosis; Oncostatin M; Osteoblast; Osteosarcoma; p53; STAT5

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; CYTOKINE; INTERLEUKIN 6; ONCOSTATIN M; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BNIP3; PROTEIN MCL 1; PROTEIN P53; STAT PROTEIN; STAT5 PROTEIN; STAUROSPORINE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CONTROLLED STUDY; CYTOSOL; DNA MICROARRAY; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRION; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RNA INTERFERENCE; SENSITIZATION; SIGNAL TRANSDUCTION; ULTRAVIOLET RADIATION;

EID: 35348850681     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210492     Document Type: Article

References (38)

1. Auernhammer CJ, Dorn F, Vlotides G, Hengge S, Kopp FB, Spoettl G et al. (2004). The oncostatin M receptor/gp130 ligand murine oncostatin M induces apoptosis in adrenocortical Y-1 tumor cells. J Endocrinol 180: 479-486.
2. Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Pouplard-Barthelaix A et al. (1997). Signaling of type II oncostatin M receptor. J Biol Chem 272: 15760-15764.
3. Battle TE, Frank DA. (2002). The role of STATs in apoptosis. Curr Mol Med 2: 381-392.
4. Baumann H, Wang Y, Richards CD, Jones CA, Black TA, Gross KW. (2000). Endotoxin-induced renal inflammatory response. Oncostatin M as a major mediator of suppressed renin expression. J Biol Chem 275: 22014-22019.
5. Bellido T, Borba VZ, Roberson P, Manolagas SC. (1997). Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 138: 3666-3676.
6. Bellido T, O'Brien CA, Roberson PK, Manolagas SC. (1998). Transcriptional activation of the p21(WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 273: 21137-21144.
7. Buitenhuis M, Coffer PJ, Koenderman L. (2004). Signal transducer and activator of transcription 5 (STAT5). Int J Biochem Cell Biol 36: 2120-2124.
8. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
9. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ. (1991). Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6: 1791-1797.
10. Chandar N, Billig B, McMaster J, Novak J. (1992). Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 65: 208-214.
11. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K et al. (1999). Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13: 2604-2616.
12. Chen SH, Benveniste EN. (2004). Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev 15: 379-391.
13. Chipoy C, Berreur M, Couillaud S, Pradal G, Vallette F, Colombeix C et al. (2004). Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res 19: 1850-1861.
14. Debierre-Grockiego F. (2004). Anti-apoptotic role of STAT5 in haematopoietic cells and in the pathogenesis of malignancies. Apoptosis 9: 717-728.
15. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M et al. (1990). p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772-5781.
16. Eskes R, Desagher S, Antonsson B, Martinou JC. (2000). Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929-935.
17. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. (1994). MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 86: 1297-1302.
18. Fuchs B, Pritchard DJ. (2002). Etiology of osteosarcoma. Clin Orthop Relat Res 397: 40-52.
19. Grant SL, Begley CG. (1999). The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today 5: 406-412.
20. Haupt S, Berger M, Goldberg Z, Haupt Y. (2003). Apoptosis - the p53 network. J Cell Sci 116: 4077-4085.
21. Heath C, Cross NC. (2004). Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1. J Biol Chem 279: 6666-6673.
22. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. (1998). Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 13: 793-802.
23. Kamiya A, Kinoshita T, Ito Y, Matsui T, Morikawa Y, Senba E et al. (1999). Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer. EMBO J 18: 2127-2136.
24. Kashkar H, Wiegmann K, Yazdanpanah B, Haubert D, Kronke M. (2005). Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J Biol Chem 280: 20804-20813.
25. Le Meur N, Lamirault G, Bihouee A, Steenman M, Bedrine-Ferran H, Teusan R et al. (2004). A dynamic, web-accessible resource to process raw microarray scan data into consolidated gene expression values: importance of replication. Nucleic Acids Res 32: 5349-5358.
26. Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE et al. (2006). Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 172: 909-921.
27. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T. (1999). STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 18: 4754-4765.
28. Oren M. (2003). Decision making by p53: life, death and cancer. Cell Death Differ 10: 431-442.
29. Qin XF, An DS, Chen IS, Baltimore D. (2003). Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 100: 183-188.
30. Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R et al. (2000). Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 106: 1095-1103.
31. Stephanou A, Brar BK, Knight RA, Latchman DS. (2000). Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 7: 329-330.
32. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. (1998). The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001-5014.
33. Thornborrow EC, Manfredi JJ. (1999). One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. J Biol Chem 274: 33747-33756.
34. Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A. (2004). STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem 279: 5811-5820.
35. Trichet V, Benezech C, Dousset C, Gesnel MC, Bonneville M, Breathnach R. (2006). Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown. J Immunol 177: 6129-6136.
36. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y et al. (1994). Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54: 3042-3048.
37. Wang X, Kua HY, Hu Y, Guo K, Zeng Q, Wu Q et al. (2006). p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 172: 115-125.
38. Wei Q. (2005). Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells. J Biol Chem 280: 37790-37797.